NovaBridge Biosciences (NBP) Earnings History
Net Loss8 years of earnings data (2017–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
NovaBridge Biosciences (NBP) Earnings Overview
As of June 23, 2026, NovaBridge Biosciences (NBP) reported trailing twelve-month net income of -$25M, reflecting +74.7% year-over-year growth. The company earned $-0.24 per diluted share over the past four quarters.
Looking at the long-term picture, NBP's historical earnings data spans multiple years. The company achieved its highest annual net income of $471M in fiscal 2020.
NovaBridge Biosciences is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), NBP has comparable earnings metrics. Compare NBP vs RCUS →
NBP Earnings vs Peers
Earnings metrics vs comparable public companies
NBP Historical Earnings Data (2017–2024)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$162M | +88.9% | -$375M | $-4.46 | - | - |
| 2023 | -$1.47B | +41.5% | -$511M | $-17.62 | -32674.0% | -11395.1% |
| 2022 | -$2.51B | -7.5% | -$366M | $-30.38 | - | - |
| 2021 | -$2.33B | -595.1% | -$2.07B | $-30.68 | -2648.7% | -2353.1% |
| 2020 | $471M | +131.7% | $156M | $6.90 | 30.5% | 10.1% |
| 2019 | -$1.49B | -268.6% | -$1.46B | $-25.53 | -4950.0% | -4883.2% |
| 2018 | -$403M | -35.1% | -$439M | $-6.92 | -749.0% | -815.6% |
| 2017 | -$298M | - | -$281M | $-5.13 | -2580.8% | -2431.2% |
Download Data
Export NBP earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NBP — Frequently Asked Questions
Quick answers to the most common questions about buying NBP stock.
What is NBP earnings per share (EPS)?
NBP trailing twelve-month (TTM) diluted EPS is $-0.24, reflecting +74.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2024 is available in the table on this page.
What is NovaBridge Biosciences's net income?
NovaBridge Biosciences (NBP) trailing twelve-month net income is $-25M as of 2024. Earnings grew +74.7% year-over-year.
Is NBP profitable?
NBP is not currently profitable on a TTM basis, reporting a net loss of $-25M. Net margin is N/A. Investors should monitor for a return to profitability.
What is NBP's earnings growth rate?
NBP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2024.
What are NBP's profit margins?
NovaBridge Biosciences net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -16.9%.
Is NBP growing earnings?
Yes, NBP earnings are accelerating — EPS growth of +74.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-25M. Earnings momentum is strengthening.
What was NBP's best earnings year?
NovaBridge Biosciences's highest annual net income on record is $471M, achieved in fiscal year 2020. Earnings history on this page spans 2017 to 2024 and includes all annual and quarterly figures.
What were NBP's earnings last quarter?
NBP's most recent reported quarter was Q3 2025. Net income was $-7M with diluted EPS of $-0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.